Home・Lista de Ações・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Abrir

SetorSaúde

42.86 3.9

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

40.67

Máximo

41.66

Indicadores-chave
By Trading Economics
Rendimento	-56M -58M
Vendas	11M 219M
EPS	0.39
Margem de lucro	-26.646
Funcionários	778
EBITDA	-50M -30M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+57.56% upside

Dividendos
By Acuity
Próximos Ganhos	3 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-313M 2.4B
Abertura anterior	38.96
Fecho anterior	42.86

Sentimento de Notícias

By Acuity

50%

134 / 339 Ranking em Healthcare

Supernus Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de set. de 2026, 22:36 UTC

Supernus Pharmaceuticals Inc is declining in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

15 de set. de 2026, 20:01 UTC

Supernus Pharmaceuticals Inc shares are lower, extending an eight-session decline. Broader market sentiment is affected by a significant drop in the NY Empire State Manufacturing Index.

14 de set. de 2026, 19:36 UTC

Supernus Pharmaceuticals Inc. is trading higher today, despite broader market pressure from rising crude oil prices and geopolitical supply concerns.

11 de set. de 2026, 20:13 UTC

Supernus Pharmaceuticals Inc. shares rose in after-market trading, reflecting broader market trends amid recent inflation data and speculation of a Federal Reserve interest rate hike.

10 de set. de 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower, continuing a five-session decline amid broader market trends following the European Central Bank's interest rate hike.

8 de set. de 2026, 20:02 UTC

Supernus Pharmaceuticals Inc. shares are lower as the Pharmaceuticals sub-sector faces significant declines, continuing a trend from the past three sessions.

2 de set. de 2026, 19:36 UTC

Supernus Pharmaceuticals is trading higher Wednesday, despite earlier pulling back from an intraday peak amid broader geopolitical tensions affecting oil prices.

1 de set. de 2026, 20:09 UTC

Supernus Pharmaceuticals Inc shares are lower today amid increased market volatility and investor concerns over rising oil prices and potential Federal Reserve interest rate hikes.

31 de ago. de 2026, 21:02 UTC

Supernus Pharmaceuticals Inc shares are higher in after-market trading, reflecting a notable rise since Monday's close. No specific news was identified to explain the movement.

28 de ago. de 2026, 19:26 UTC

Supernus Pharmaceuticals Inc. shares are trading lower, continuing a trend of declines amid broader market concerns about inflation and Federal Reserve remarks on price stability.

27 de ago. de 2026, 20:07 UTC

Supernus Pharmaceuticals Inc shares are declining, continuing a downward trend since Wednesday. Broader market conditions may be contributing to this weakness.

26 de ago. de 2026, 20:08 UTC

Supernus Pharmaceuticals Inc shares are lower today, driven by declines in the Pharmaceuticals sub-sector. The stock is trading near its one-month low.

25 de ago. de 2026, 19:16 UTC

Supernus Pharmaceuticals Inc. shares are higher today amid a broader market rally, supported by falling crude oil prices and lower treasury yields.

24 de ago. de 2026, 19:26 UTC

Supernus Pharmaceuticals Inc. shares are lower, continuing a four-session decline amid broader market volatility and geopolitical tensions affecting oil supply.

21 de ago. de 2026, 20:01 UTC

Supernus Pharmaceuticals Inc. shares are lower today, aligning with broader market weakness and finishing at the lowest point observed during the session.

20 de ago. de 2026, 21:01 UTC

Supernus Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of three consecutive daily declines amid broader market pressures.

18 de ago. de 2026, 19:36 UTC

Supernus Pharmaceuticals Inc is trading higher, maintaining upward momentum since Monday. The stock remains above its 20-day moving average and near a one-month high.

17 de ago. de 2026, 19:26 UTC

News

Supernus Pharmaceuticals Inc is featured in a cautionary analysis from Yahoo Finance, citing below-average sales growth and declining cash flow margin. The stock is roughly flat today.

14 de ago. de 2026, 19:16 UTC

Macro Event

Supernus Pharmaceuticals Inc shares are higher, maintaining momentum since Thursday amid broader market caution following a decline in U.S. retail sales.

13 de ago. de 2026, 19:16 UTC

Supernus Pharmaceuticals Inc shares are lower Thursday, pulling back from an early high. No specific news was identified to explain the movement.

12 de ago. de 2026, 19:51 UTC

Supernus Pharmaceuticals shares are higher amid positive market sentiment following an inflation report and strength in technology stocks.

11 de ago. de 2026, 20:01 UTC

Supernus Pharmaceuticals Inc shares are lower as the Pharmaceuticals sector declines. The stock is trading with unusually high volume today.

10 de ago. de 2026, 22:46 UTC

Supernus Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Monday's close amid broader market reassessments of interest rate hikes.

7 de ago. de 2026, 19:31 UTC

Supernus Pharmaceuticals Inc. is trading higher, influenced by an advancing overall market amid positive macroeconomic indicators, despite ongoing geopolitical tensions.

6 de ago. de 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday's close, amid unusually high market volume.

5 de ago. de 2026, 20:03 UTC

Supernus Pharmaceuticals Inc shares are higher Wednesday, driven by high market volume and broader positive sentiment amid declining oil prices and geopolitical optimism.

4 de ago. de 2026, 19:51 UTC

News

Supernus Pharmaceuticals is declining following its merger announcement with Indivior and a quarterly revenue report of $219 million amid a net loss of $58 million.

3 de ago. de 2026, 19:51 UTC

Social Media

News

Event

Supernus Pharmaceuticals announced a merger with Indivior, creating a company with $2.2 billion in revenue. Shares are higher following strong Q2 earnings that beat estimates.

31 de jul. de 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, reversing from an early gain amid broader market concerns over rising Treasury yields and crude oil prices.

30 de jul. de 2026, 14:33 UTC

Supernus Pharmaceuticals Inc. shares are lower, impacted by weakness in the pharmaceuticals sub-sector. The stock briefly rebounded earlier in the session before declining.

Comparação entre Pares

Variação de preço

Supernus Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

57.56% parte superior

Previsão para 12 meses

Média 65.2 USD 57.56%

Máximo 67 USD

Mínimo 63 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Supernus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Supernus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

134 / 339 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.